Diagnosis and treatment strategies for solid organ transplant recipients with SARS-CoV-2 infection

Ju Chunrong; Xu Xin; Xue Wujun

doi:10.3969/j.issn.1674-7445.2023.02.002

Volume 14 Issue 2

Mar. 2023

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2023 > 14(2): 183-193

Ju Chunrong, Xu Xin, Xue Wujun. Diagnosis and treatment strategies for solid organ transplant recipients with SARS-CoV-2 infection[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 183-193. doi: 10.3969/j.issn.1674-7445.2023.02.002

Citation:

PDF( 6641 KB)

Diagnosis and treatment strategies for solid organ transplant recipients with SARS-CoV-2 infection

doi: 10.3969/j.issn.1674-7445.2023.02.002

Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510012, China

More Information

Corresponding author: Xue Wujun, Email: xwujun126@xjtu.edu.cn
Received Date: 2023-01-18
Available Online: 2023-03-15
Publish Date: 2023-03-15

Abstract

Abstract

Due to long-term use of immunosuppressive agents, solid organ transplant recipients (SOTR) belong to high-risk populations of multiple pathogenic infection, including SARS-CoV-2. In addition, SOTR are constantly complicated by chronic diseases, such as hypertension and diabetes mellitus, etc. After infected with SARS-CoV-2, the critically ill rate and fatality of SOTR are higher than those of the general population, which captivates widespread attention from experts in the field of organ transplantation. Omicrone variant is currently the significant pandemic strain worldwide, rapidly spreading to more than 100 countries worldwide and causing broad concern. According to the latest international guidelines on the diagnosis and treatment of SARS-CoV-2 infection and relevant expert consensus in China combined with current domestic situation of SARS-CoV-2 pandemic and China's "diagnosis and treatment regimen for SARS-CoV-2 infection (Trial Version 10)", the epidemiology, clinical manifestations and prognosis, diagnosis, clinical classification and treatment of SARS-CoV-2 infection were briefly reviewed.
- SARS-CoV-2,
- Solid organ transplant recipient,
- Epidemiology,
- Nucleic acid test,
- Nematvir/ritonavir,
- Remdesivir,
- Renal replacement therapy,
- Transplant-associated thrombotic microangiopathy,
- Multi-disciplinary team (MDT)

FullText(HTML)

References(40)

References

[1]	Weekly epidemiological update on COVID-19 - 14 December 2022[EB/OL]. [2022-12-15]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---14-december-2022.
[2]	ZHONG Z, ZHANG Q, XIA H, et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients[J]. Am J Transplant, 2020, 20(7): 1916-1921. DOI: 10.1111/ajt.15928.
[3]	TAHA M, SHARMA A, TAHA M, et al. Coronavirus disease 2019 in immunocompromised organ transplant recipients: a case report and review of the literature[J]. Transplant Proc, 2020, 52(9): 2698-2702. DOI: 10.1016/j.transproceed.2020.07.014.
[4]	MOHAMMED AH, BLEBIL A, DUJAILI J, et al. The risk and impact of COVID-19 pandemic on immunosuppressed patients: cancer, HIV, and solid organ transplant recipients[J]. AIDS Rev, 2020, 22(3): 151-157. DOI: 10.24875/AIDSRev.20000052.
[5]	YI SG, ROGERS AW, SAHARIA A, et al. Early experience with COVID-19 and solid organ transplantation at a us high-volume transplant center[J]. Transplantation, 2020, 104(11): 2208-2214. DOI: 10.1097/TP.0000000000003339.
[6]	NIMMO A, GARDINER D, USHIRO-LUMB I, et al. The global impact of COVID-19 on solid organ transplantation: two years into a pandemic[J]. Transplantation, 2022, 106(7): 1312-1329. DOI: 10.1097/TP.0000000000004151.
[7]	CALLAWAY E. Heavily mutated Omicron variant puts scientists on alert[J]. Nature, 2021, 600(7887): 21. DOI: 10.1038/d41586-021-03552-w.
[8]	MALLAPATY S. Omicron-variant border bans ignore the evidence, say scientists[J]. Nature, 2021, 600(7888): 199. DOI: 10.1038/d41586-021-03608-x.
[9]	KANNAN S, SHAIK SYED ALI P, SHEEZA A. Omicron (B. 1.1.529) - variant of concern - molecular profile and epidemiology: a mini review[J]. Eur Rev Med Pharmacol Sci, 2021, 25(24): 8019-8022. DOI: 10.26355/eurrev_202112_27653.
[10]	陈广, 陈韬, 舒赛男, 等. 新型冠状病毒奥密克戎变异株感染诊治快速指引[J]. 中华临床感染病杂志, 2023, 16(1): 21-27. DOI: 10.3760/cma.j.issn.1674-2397.2023.01.003. CHEN G, CHEN T, SHU SN, et al. Quick guideline for diagnosis and treatment of SARS-CoV-2 Omicron variant infection[J]. Chin J Clin Infect Dis, 2023, 16(1): 21-27. DOI: 10.3760/cma.j.issn.1674-2397.2023.01.003.
[11]	国家卫生健康委员会办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中国病毒病杂志, 2022, 12(3): 161-169. DOI: 10.16505/j.2095-0136.2022.0023. General Office of the National Health Commission, State Administration of Traditional Chinese Medicine. Guidelines for the diagnosis and treatment of coronavirus disease 2019(trial version ninth)[J]. Chin J Viral Dis, 2022, 12(3): 161-169. DOI: 10.16505/j.2095-0136.2022.0023.
[12]	PULLIAM JRC, VAN SCHALKWYK C, GOVENDER N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa[J]. Science, 2022, 376(6593): eabn4947. DOI: 10.1126/science.abn4947.
[13]	VAN DOREMALEN N, BUSHMAKER T, MORRIS DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1[J]. N Engl J Med, 2020, 382(16): 1564-1567. DOI: 10.1056/NEJMc2004973.
[14]	HIROSE R, ITOH Y, IKEGAYA H, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: both Omicron BA. 1 and BA. 2 have higher stability[J]. Clin Microbiol Infect, 2022, 28(11): 1486-1491. DOI: 10.1016/j.cmi.2022.05.020.
[15]	ARAF Y, AKTER F, TANG YD, et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines[J]. J Med Virol, 2022, 94(5): 1825-1832. DOI: 10.1002/jmv.27588.
[16]	CHEN Z, ZHANG Y, WANG M, et al. Humoral and cellular immune responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review[J]. Int J Biol Sci, 2022, 18(12): 4629-4641. DOI: 10.7150/ijbs.73583.
[17]	胡欢, 陆家海. 基于同一健康策略应对新发及再发传染病[J]. 中山大学学报(医学科学版), 2022, 43(5): 705-711. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0503. HU H, LU JH. Coping with emerging and reemerging infectious diseases based on the one health strategy[J]. J Sun Yat-Sen Univ(Med Sci), 2022, 43(5): 705-711. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0503.
[18]	刘莹, 李美瑜, 李锋, 等. 广州市输入性2019新型冠状病毒奥密克戎与德尔塔变异株感染者的临床特征分析[J]. 中华传染病杂志, 2022, 40(10): 584-590. DOI: 10.3760/cma.j.cn311365-20220415-00136. LIU Y, LI MY, LI F, et al. Clinical characteristics of imported patients infected with 2019 novel coronavirus Omicron variants and Delta variants in Guangzhou City[J]. Chin J Infect Dis, 2022, 40(10): 584-590. DOI: 10.3760/cma.j.cn311365-20220415-00136.
[19]	RAJA MA, MENDOZA MA, VILLAVICENCIO A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature[J]. Transplant Rev (Orlando), 2021, 35(1): 100588. DOI: 10.1016/j.trre.2020.100588.
[20]	HEANEY K, RITCHIE AV, HENRY R, et al. Evaluation of sample pooling using the SAMBA Ⅱ SARS-CoV-2 test[J]. J Virol Methods, 2022, 299: 114340. DOI: 10.1016/j.jviromet.2021.114340.
[21]	国家卫生健康委办公厅, 国家中医药局综合司. 关于印发新型冠状病毒感染诊疗方案(试行第十版)的通知[A/OL]. [2023-01-06]. http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml.
[22]	VILLAMARÍN M, MÁRQUEZ-ALGABA E, ESPERALBA J, et al. Preliminary clinical experience of molnupiravir to prevent progression of COVID-19 in kidney transplant recipients[J]. Transplantation, 2022, 106(11): 2200-2204. DOI: 10.1097/TP.0000000000004306.
[23]	BADRI P, DUTTA S, COAKLEY E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir[J]. Am J Transplant, 2015, 15(5): 1313-1322. DOI: 10.1111/ajt.13111.
[24]	LANGE NW, SALERNO DM, JENNINGS DL, et al. Nirmatrelvir/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants[J]. Am J Transplant, 2022, 22(7): 1925-1926. DOI: 10.1111/ajt.16955.
[25]	KUMAR D, TRIVEDI N. Disease-drug and drug-drug interaction in COVID-19: risk and assessment[J]. Biomed Pharmacother, 2021, 139: 111642. DOI: 10.1016/j.biopha.2021.111642.
[26]	NWABUFO CK, BENDAYAN R. Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs[J]. Trends Pharmacol Sci, 2022, 43(12): 1041-1054. DOI: 10.1016/j.tips.2022.09.005.
[27]	KARAŹNIEWICZ-ŁADA M, GŁÓWKA AK, MIKULSKA AA, et al. Pharmacokinetic drug-drug interactions among antiepileptic drugs, including CBD, drugs used to treat COVID-19 and nutrients[J]. Int J Mol Sci, 2021, 22(17): 9582. DOI: 10.3390/ijms22179582.
[28]	陈艳芳, 邓西龙, 梁嘉碧. 新型冠状病毒肺炎抗病毒治疗临床药学指引[J]. 今日药学, 2022, 32(8): 561-572. https://www.cnki.com.cn/Article/CJFDTOTAL-YAXU202208001.htm CHEN YF, DENG XL, LIANG JB. Clinical pharmaceutical guidelines for anti-respiratory virus drugs[J]. Pharm Today, 2022, 32(8): 561-572. https://www.cnki.com.cn/Article/CJFDTOTAL-YAXU202208001.htm
[29]	LOO YM, MCTAMNEY PM, ARENDS RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans[J]. Sci Transl Med, 2022, 14(635): eabl8124. DOI: 10.1126/scitranslmed.abl8124.
[30]	HAMMITT LL, DAGAN R, YUAN Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants[J]. N Engl J Med, 2022, 386(9): 837-846. DOI: 10.1056/NEJMoa2110275.
[31]	SHEN C, WANG Z, ZHAO F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma[J]. JAMA, 2020, 323(16): 1582-1589. DOI: 10.1001/jama.2020.4783.
[32]	PASRIJA R, NAIME M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease[J]. Int Immunopharmacol, 2021, 90: 107225. DOI: 10.1016/j.intimp.2020.107225.
[33]	PUM A, ENNEMOSER M, ADAGE T, et al. Cytokines and chemokines in SARS-CoV-2 infections-therapeutic strategies targeting cytokine storm[J]. Biomolecules, 2021, 11(1): 91. DOI: 10.3390/biom11010091.
[34]	Recovery Collaborative Group, HORBY P, LIM WS, et al. Dexamethasone in hospitalized patients with COVID-19[J]. N Engl J Med, 2021, 384(8): 693-704. DOI: 10.1056/NEJMoa2021436.
[35]	凌云, 张丽荣, 彭军, 等. 新型冠状病毒肺炎的预防和药物治疗进展[J]. 转化医学杂志, 2022, 11(3): 197-201. DOI: 10.3969/j.issn.2095-3097.2022.03.016. LING Y, ZHANG LR, PENG J, et al. Progress in prevention of COVID-19 and its medical treatment with antiviral drugs against SARS-CoV-2[J]. Transl Med J, 2022, 11(3): 197-201. DOI: 10.3969/j.issn.2095-3097.2022.03.016.
[36]	SUH YJ, HONG H, OHANA M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis[J]. Radiology, 2021, 298(2): E70-E80. DOI: 10.1148/radiol.2020203557.
[37]	PRINCE MR, DEV H, LANE EG, et al. Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism[J]. J Thromb Thrombolysis, 2022, 54(3): 431-437. DOI: 10.1007/s11239-022-02666-w.
[38]	GUÉRIN C, ALBERT RK, BEITLER J, et al. Prone position in ARDS patients: why, when, how and for whom[J]. Intensive Care Med, 2020, 46(12): 2385-2396. DOI: 10.1007/s00134-020-06306-w.
[39]	KATIRA BH, OSADA K, ENGELBERTS D, et al. Positive end-expiratory pressure, pleural pressure, and regional compliance during pronation: an experimental study[J]. Am J Respir Crit Care Med, 2021, 203(10): 1266-1274. DOI: 10.1164/rccm.202007-2957OC.
[40]	BERG RMG, HARTMANN JP, IEPSEN UW, et al. Therapeutic benefits of proning to improve pulmonary gas exchange in severe respiratory failure: focus on fundamentals of physiology[J]. Exp Physiol, 2022, 107(7): 759-770. DOI: 10.1113/EP089405.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(6) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (373) PDF downloads(100)

Diagnosis and treatment strategies for solid organ transplant recipients with SARS-CoV-2 infection

doi: 10.3969/j.issn.1674-7445.2023.02.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Diagnosis and treatment strategies for solid organ transplant recipients with SARS-CoV-2 infection

doi: 10.3969/j.issn.1674-7445.2023.02.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content